

Olivier Chinot, Pu-Ph

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/630657/olivier-chinot-pu-ph-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116
papers

7,315
citations

43
h-index

84
g-index

123
ext. papers

8,650
ext. citations

6.2
avg, IF

5.05
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 116 | Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.. <i>Journal of Neuro-Oncology</i> , 2022 , 156, 615 | 4.8 | 1 |
| 115 | The creation and implementation of advanced practice nursing in France: Experiences from the field. <i>International Nursing Review</i> , 2021 , 68, 412-419 | 3.5 | 1 |
| 114 | Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 552-557 | 12.9 | 38 |
| 113 | The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019 , 116, 190-198 | 7.5 | 11 |
| 112 | Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 823-833 | 2.2 | 92 |
| 111 | Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. <i>Neuro-Oncology</i> , 2019 , 21, 1447-1457 | 1 | 19 |
| 110 | Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients. <i>Anticancer Research</i> , 2019 , 39, 1035-1041 | 2.3 | 3 |
| 109 | Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016. <i>Journal of Neuro-Oncology</i> , 2019 , 142, 511-520 | 4.8 | 5 |
| 108 | Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 537-538 | 8.8 | 8 |
| 107 | Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019 , 25, 1809-1816 | 12.9 | 59 |
| 106 | Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. <i>Neuro-Oncology</i> , 2018 , 20, 1525-1535 | 1 | 12 |
| 105 | Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018 , 20, 1240-1250 | 1 | 39 |
| 104 | The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , 2018 , 135, 601-615 | 14.3 | 54 |
| 103 | Clustering based on unsupervised binary trees to define subgroups of cancer patients according to symptom severity in cancer. <i>Quality of Life Research</i> , 2018 , 27, 555-565 | 3.7 | 1 |
| 102 | Analyse psychologique interprétative auprès de conjoints de patients présentant une tumeur cérébrale maligne. Soins de support et rôle des aidants. <i>Annales Medico-Psychologiques</i> , 2018 , 176, 448-455 | 0.2 | 1 |
| 101 | Dyadic effects of coping strategies, time perspectives, and personality on the quality of life of cancer patients and their caregivers. <i>Psycho-Oncology</i> , 2018 , 27, 590-599 | 3.9 | 15 |
| 100 | Coping strategies and quality of life: a longitudinal study of high-grade glioma patient-caregiver dyads. <i>Health and Quality of Life Outcomes</i> , 2018 , 16, 157 | 3 | 16 |

| | | | |
|----|---|------|-----|
| 99 | Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression. <i>Oncotarget</i> , 2018 , 9, 10175-10183 | 3.3 | 15 |
| 98 | Differential scanning calorimetry of plasma in glioblastoma: toward a new prognostic / monitoring tool. <i>Oncotarget</i> , 2018 , 9, 9391-9399 | 3.3 | 10 |
| 97 | Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study. <i>European Journal of Cancer</i> , 2017 , 73, 30-37 | 7.5 | 47 |
| 96 | European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology, The</i> , 2017 , 18, e315-e329 | 21.7 | 599 |
| 95 | Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. <i>Journal of Neuro-Oncology</i> , 2017 , 132, 433-437 | 4.8 | 8 |
| 94 | Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. <i>New England Journal of Medicine</i> , 2017 , 376, 1027-1037 | 59.2 | 525 |
| 93 | Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. <i>Journal of Neurosurgery</i> , 2017 , 127, 660-669 | 3.2 | 27 |
| 92 | Evidence-based management of adult patients with diffuse glioma - AuthorsReply. <i>Lancet Oncology, The</i> , 2017 , 18, e430-e431 | 21.7 | 4 |
| 91 | Domains of quality of life freely expressed by cancer patients and their caregivers: contribution of the SEIQoL. <i>Health and Quality of Life Outcomes</i> , 2017 , 15, 99 | 3 | 8 |
| 90 | Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients. <i>Cancer Biomarkers</i> , 2017 , 20, 435-441 | 3.8 | 10 |
| 89 | Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. <i>International Journal of Molecular Sciences</i> , 2017 , 18, | 6.3 | 20 |
| 88 | Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma. <i>Oncotarget</i> , 2017 , 8, 55361-55373 | 3.3 | 12 |
| 87 | Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. <i>Neuro-Oncology</i> , 2017 , 19, 422-429 | 1 | 17 |
| 86 | Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. <i>Acta Neuropathologica</i> , 2016 , 132, 625-34 | 14.3 | 72 |
| 85 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 731-9 ^{2.2} | | 108 |
| 84 | Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. <i>Neuro-Oncology</i> , 2016 , 18, 1297-303 | 1 | 80 |
| 83 | A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016 , 18, 1146-56 ¹ | | 135 |
| 82 | Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS). <i>Blood</i> , 2016 , 128, 782-782 | 2.2 | 17 |

| | | | |
|----|---|------|-----|
| 81 | Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network. <i>Blood</i> , 2016 , 128, 785-785 | 2.2 | 35 |
| 80 | The French LOC Network for Primary CNS Lymphoma (PCNSL) Patients: What Can We Learn from a Large National Database?. <i>Blood</i> , 2016 , 128, 926-926 | 2.2 | 2 |
| 79 | Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. <i>Oncotarget</i> , 2016 , 7, 61916-61929 ^{3:3} | 3:3 | 34 |
| 78 | Molecular heterogeneity of glioblastomas: does location matter?. <i>Oncotarget</i> , 2016 , 7, 902-13 | 3:3 | 15 |
| 77 | MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. <i>Oncotarget</i> , 2016 , 7, 18531-40 | 3:3 | 31 |
| 76 | Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma. <i>Cancer Medicine</i> , 2016 , 5, 1753-64 | 4.8 | 12 |
| 75 | Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology, The</i> , 2016 , 17, 1533-1542 | 21.7 | 77 |
| 74 | Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology, The</i> , 2016 , 17, 1521-1532 ^{2:7} 294 | 21.7 | 294 |
| 73 | Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016 , 130, 431-437 | 4.8 | 7 |
| 72 | Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. <i>Neurology</i> , 2015 , 85, 1325-31 | 6.5 | 25 |
| 71 | MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma. <i>Neuro-Oncology</i> , 2015 , 17, 1174-6 | 1 | 37 |
| 70 | Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. <i>Lancet Haematology, the</i> , 2015 , 2, e251-9 | 14.6 | 115 |
| 69 | Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. <i>Journal of Neuro-Oncology</i> , 2015 , 124, 33-43 | 4.8 | 28 |
| 68 | ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015 , 17, v12.2-v12 | 1 | 1 |
| 67 | Adrenomedullin blockade induces regression of tumor neovessels through interference with vascular endothelial-cadherin signalling. <i>Oncotarget</i> , 2015 , 6, 7536-53 | 3:3 | 12 |
| 66 | Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway. <i>Oncotarget</i> , 2015 , 6, 11664-75 | 3:3 | 38 |
| 65 | Relationships Between Dose Intensity, Toxicity, and Outcome in Patients with Oligodendroglial Tumors Treated with the PCV Regimen. <i>Anticancer Research</i> , 2015 , 35, 2901-8 | 2:3 | 3 |
| 64 | Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France. <i>Neurosurgical Review</i> , 2014 , 37, 415-23; discussion 423-4 | 3:9 | 31 |

| | | | |
|----|---|------|-----|
| 63 | Ex vivo cultures of glioblastoma in three-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening. <i>Experimental Cell Research</i> , 2014 , 321, 99-108 | 4.2 | 45 |
| 62 | MALDI imaging and in-source decay for top-down characterization of glioblastoma. <i>Proteomics</i> , 2014 , 14, 1290-301 | 4.8 | 22 |
| 61 | EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. <i>Lancet Oncology, The</i> , 2014 , 15, e395-403 | 21.7 | 498 |
| 60 | Predictive biomarkers investigated in glioblastoma. <i>Expert Review of Molecular Diagnostics</i> , 2014 , 14, 883-93 | 3.8 | 13 |
| 59 | Monitoring therapeutic monoclonal antibodies in brain tumor. <i>MAbs</i> , 2014 , 6, 1385-93 | 6.6 | 12 |
| 58 | Assessing the quality of life among caregivers of patients with gliomas. <i>Neuro-Oncology Practice</i> , 2014 , 1, 191-197 | 2.2 | 13 |
| 57 | Bing-Neel syndrome: a cerebral Richter syndrome?. <i>Neurology India</i> , 2014 , 62, 229-30 | 0.7 | 2 |
| 56 | An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas. <i>BioMed Research International</i> , 2014 , 2014, 282815 | 3 | 6 |
| 55 | Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. <i>Neuro-Oncology</i> , 2014 , 16, 392-9 | 1 | 43 |
| 54 | Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. <i>Neuro-Oncology</i> , 2014 , 16, 662-70 | 1 | 55 |
| 53 | End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo. <i>Oncotarget</i> , 2014 , 5, 12769-87 | 3.3 | 22 |
| 52 | Tubulin isoforms identified in the brain by MALDI in-source decay. <i>Journal of Proteomics</i> , 2013 , 79, 172-93.9 | 9 | 9 |
| 51 | High-grade glioma in elderly patients: can the oncogeriatrician help?. <i>Clinical Interventions in Aging</i> , 2013 , 8, 1617-24 | 4 | 5 |
| 50 | Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. <i>Journal of Neuro-Oncology</i> , 2012 , 110, 205-13 | 4.8 | 26 |
| 49 | The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer. <i>European Journal of Cancer</i> , 2012 , 48, 904-11 | 7.5 | 57 |
| 48 | Association of carcinoid tumor and low grade glioma. <i>World Journal of Surgical Oncology</i> , 2012 , 10, 236 | 3.4 | 1 |
| 47 | SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. <i>PLoS ONE</i> , 2012 , 7, e45950 | 3.7 | 23 |
| 46 | A multicenter prospective observational study of the conformity of temozolomide prescriptions in France. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 828-34 | 2.6 | 2 |

| | | | |
|----|--|------|-----|
| 45 | Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltransferase in a series of 100 glioblastoma patients. <i>Cancer</i> , 2012 , 118, 4201-11 | 6.4 | 149 |
| 44 | Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 527-35 | 4.8 | 41 |
| 43 | FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. <i>Neuro-Oncology</i> , 2012 , 14, 649-57 | 1 | 64 |
| 42 | Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. <i>Clinical Cancer Research</i> , 2012 , 18, 5203-11 | 12.9 | 170 |
| 41 | Adrenomedullin expression and regulation in human glioblastoma, cultured human glioblastoma cell lines and pilocytic astrocytoma. <i>European Journal of Cancer</i> , 2011 , 47, 1727-35 | 7.5 | 14 |
| 40 | Reirradiation and concomitant metronomic temozolomide: an efficient combination for local control in medulloblastoma disease?. <i>Journal of Pediatric Hematology/Oncology</i> , 2011 , 33, 600-4 | 1.2 | 21 |
| 39 | Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2937-45 | 3.1 | 49 |
| 38 | Links between private habits, psychological stress and brain cancer: a case-control pilot study in France. <i>Journal of Neuro-Oncology</i> , 2011 , 103, 307-16 | 4.8 | 27 |
| 37 | Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?. <i>Journal of Neuro-Oncology</i> , 2011 , 104, 323-30 | 4.8 | 48 |
| 36 | IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. <i>Journal of Neuro-Oncology</i> , 2011 , 105, 591-600 | 4.8 | 55 |
| 35 | Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3050-5 | 2.2 | 167 |
| 34 | Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab. <i>Journal of Clinical Oncology</i> , 2011 , 29, e308-11 | 2.2 | 21 |
| 33 | Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. <i>Neuro-Oncology</i> , 2010 , 12, 725-35 | 1 | 130 |
| 32 | Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. <i>Neuro-Oncology</i> , 2010 , 12, 976-84 | 1 | 59 |
| 31 | Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. <i>Neuro-Oncology</i> , 2010 , 12, 401-8 | 1 | 147 |
| 30 | An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. <i>Molecular Cancer</i> , 2010 , 9, 234 | 42.1 | 34 |
| 29 | Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression. <i>Human Pathology</i> , 2010 , 41, 815-23 | 3.7 | 16 |
| 28 | Occupational and environmental risk factors for brain cancer: a pilot case-control study in France. <i>Presse Medicale</i> , 2010 , 39, e35-44 | 2.2 | 10 |

| | | | |
|----|--|------|-----|
| 27 | Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers. <i>Oncology Letters</i> , 2010 , 1, 883-884 | 2.6 | 5 |
| 26 | Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. <i>Acta Neuropathologica</i> , 2010 , 120, 719-29 | 14.3 | 233 |
| 25 | Up-front temozolomide in elderly patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2010 , 99, 89-94 | 4.8 | 35 |
| 24 | Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. <i>BMC Cancer</i> , 2010 , 10, 91 | 4.8 | 66 |
| 23 | Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. <i>FASEB Journal</i> , 2009 , 23, 3424-35 | 0.9 | 50 |
| 22 | Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. <i>Cancer</i> , 2009 , 115, 4783-94 | 6.4 | 67 |
| 21 | Infratentorial ependymomas: prognostic factors and outcome analysis in a multi-center retrospective series of 106 adult patients. <i>Acta Neurochirurgica</i> , 2009 , 151, 947-60 | 3 | 27 |
| 20 | High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. <i>Acta Neuropathologica</i> , 2009 , 118, 745-54 | 14.3 | 54 |
| 19 | Genesis and biology of vestibular schwannomas. <i>Progress in Neurological Surgery</i> , 2008 , 21, 24-31 | 1.4 | 24 |
| 18 | A case of cerebello-thalamo-cortical diaschisis. <i>Clinical Nuclear Medicine</i> , 2008 , 33, 717-8 | 1.7 | 1 |
| 17 | FDG-PET to predict different patterns of progression in multicentric glioblastoma: a case report. <i>Journal of Neuro-Oncology</i> , 2008 , 90, 47-51 | 4.8 | 11 |
| 16 | Supratentorial ependymomas: prognostic factors and outcome analysis in a retrospective series of 46 adult patients. <i>Cancer</i> , 2008 , 113, 175-85 | 6.4 | 51 |
| 15 | Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. <i>Journal of Neuro-Oncology</i> , 2007 , 85, 207-11 | 4.8 | 113 |
| 14 | Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. <i>Brain</i> , 2007 , 130, 1338-49 | 11.2 | 100 |
| 13 | Radiotherapy for glioblastoma in the elderly. <i>New England Journal of Medicine</i> , 2007 , 356, 1527-35 | 59.2 | 602 |
| 12 | Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy. <i>Magnetic Resonance in Medicine</i> , 2006 , 55, 1236-45 | 4.4 | 58 |
| 11 | Deletions of chromosomes 1p and 19q are detectable on frozen smears of gliomas by FISH: usefulness for stereotactic biopsies. <i>Journal of Neuro-Oncology</i> , 2004 , 68, 141-9 | 4.8 | 18 |
| 10 | Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. <i>International Journal of Cancer</i> , 2004 , 108, 797-804 | 7.5 | 105 |

| | | | |
|---|--|-----|-----|
| 9 | Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. <i>Journal of Neurosurgery</i> , 2003 , 98, 269-76 | 3.2 | 87 |
| 8 | PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 52, 592-8 | 4 | 286 |
| 7 | Histological and MR correlations in Gliomatosis cerebri. <i>Journal of Neuro-Oncology</i> , 2002 , 59, 249-59 | 4.8 | 35 |
| 6 | Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. <i>American Journal of Pathology</i> , 2002 , 160, 1279-92 | 5.8 | 109 |
| 5 | Chemotherapy for the treatment of oligodendroglial tumors. <i>Seminars in Oncology</i> , 2001 , 28, 13-8 | 5.5 | 35 |
| 4 | Long-term tumor control and functional outcome in patients with cavernous sinus meningiomas treated by radiotherapy with or without previous surgery: is there an alternative to aggressive tumor removal?. <i>Neurosurgery</i> , 2001 , 48, 285-94; discussion 294-6 | 3.2 | 109 |
| 3 | Divergent effect of TGFbeta1 on growth and proteolytic modulation of human prostatic-cancer cell lines. <i>International Journal of Cancer</i> , 1996 , 66, 796-801 | 7.5 | 16 |
| 2 | Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer. <i>International Journal of Cancer</i> , 1995 , 61, 7-12 | 7.5 | 32 |
| 1 | Biological heterogeneity of ER-positive breast cancers in the post-menopausal population. <i>International Journal of Cancer</i> , 1994 , 59, 17-9 | 7.5 | 19 |